Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
8.72
+0.43 (5.19%)
At close: Nov 7, 2025, 4:00 PM EST
8.73
+0.01 (0.11%)
After-hours: Nov 7, 2025, 7:59 PM EST
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $28.30M in the quarter ending June 30, 2025, a decrease of -43.24%. This brings the company's revenue in the last twelve months to $122.12M, down -25.47% year-over-year. In the year 2024, Arcturus Therapeutics Holdings had annual revenue of $152.31M, down -8.69%.
Revenue (ttm)
$122.12M
Revenue Growth
-25.47%
P/S Ratio
1.93
Revenue / Employee
$693,875
Employees
176
Market Cap
236.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
| Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
| Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
| Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
| Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARCT News
- 4 days ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 11 days ago - Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 - Business Wire
- 17 days ago - Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture - Benzinga
- 17 days ago - Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results - Invezz
- 17 days ago - Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire
- 3 months ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress - Business Wire
- 3 months ago - Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 - Business Wire